黑色素瘤中分子改变与免疫反应的相互作用。
Interaction of molecular alterations with immune response in melanoma.
作者信息
Szczepaniak Sloane Robert A, Gopalakrishnan Vancheswaran, Reddy Sangeetha M, Zhang Xue, Reuben Alexandre, Wargo Jennifer A
机构信息
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681.
Abstract
Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42. © 2017 American Cancer Society.
摘要
在黑色素瘤治疗中，分子靶向疗法和免疫疗法取得了重大进展，目前美国食品药品监督管理局已批准多种方案用于治疗IV期疾病患者。然而，这两类药物都存在治疗耐药性问题，且缺乏可靠的治疗反应和耐药生物标志物。通过临床前研究和转化研究，我们对其作用机制有了更深入的了解，这为提高治疗患者的反应率和生存率提供了潜在策略。全面了解黑色素瘤中常见突变的免疫效应至关重要，同样重要的是要认识到导致免疫治疗耐药的分子机制。本文将讨论这些机制及其相互作用。《癌症》2017年；123:2130 - 42。© 2017美国癌症协会。
相似文献
1
Interaction of molecular alterations with immune response in melanoma.黑色素瘤中分子改变与免疫反应的相互作用。
Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681.
2
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.黑色素瘤分子靶向治疗耐药的克服机制与策略
Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435.
3
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.依匹单抗、威罗非尼、达拉非尼和曲美替尼：BRAF 突变型恶性黑色素瘤临床治疗中的协同竞争者。
Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24.
4
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.MEK 抑制可能会增加接受检查点阻断治疗的NRAS 突变黑色素瘤患者的生存：对 364 名患者进行回顾性多中心分析的结果。
Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.
5
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.针对 BRAF 突变型转移性黑色素瘤的靶向药物或免疫肿瘤疗法作为一线治疗：一项真实世界研究。
Future Oncol. 2019 Sep 1;15(25):2933-2942. doi: 10.2217/fon-2018-0964. Epub 2019 Feb 25.
6
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较（COMBI-v）：一项开放标签、随机、3 期临床试验结果。
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
7
Rapid evolution of combination therapy in melanoma.黑色素瘤联合治疗的快速发展
N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158.
8
Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".晚期黑色素瘤治疗中的争议：“青一块紫一块”中的“灰色地带”
Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23.
9
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.早期达拉非尼/曲美替尼联合治疗 BRAF 突变转移性黑色素瘤耐药中 MAPK 再激活增加。
Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.
10
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?采用免疫疗法或靶向疗法对高危黑色素瘤进行辅助治疗会影响复发时的治疗选择吗？
Clin Adv Hematol Oncol. 2018 May;16(5):353-355.
引用本文的文献
1
Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.调节性干扰素刺激基因的拮抗作用增强了STING激动剂的抗黑色素瘤疗效。
Front Immunol. 2024 Jan 18;15:1334769. doi: 10.3389/fimmu.2024.1334769. eCollection 2024.
2
Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.重新审视 B-RAF 激酶在黑色素瘤治疗中的作用。
Curr Med Chem. 2024;31(15):2003-2020. doi: 10.2174/0109298673258495231011065225.
3
Prognostic nomogram for external ear melanoma patients in the elderly: a SEER-based study.老年外耳道黑色素瘤患者的预后列线图：一项基于 SEER 的研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12241-12248. doi: 10.1007/s00432-023-05098-y. Epub 2023 Jul 11.
4
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.仑伐替尼联合帕博利珠单抗挽救治疗乏细胞型甲状腺未分化癌一例报告
Curr Oncol. 2021 Dec 16;28(6):5401-5407. doi: 10.3390/curroncol28060450.
5
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.NRAS 突变与抗 PD-1 单药治疗晚期黑色素瘤的临床结局的关联：四项亚洲临床试验的汇总分析。
Front Immunol. 2021 Jul 5;12:691032. doi: 10.3389/fimmu.2021.691032. eCollection 2021.
6
Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.使用机器学习和药效计量学建模鉴定高维组学生物标志物以预测肿瘤生长动态。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):350-361. doi: 10.1002/psp4.12603. Epub 2021 Apr 8.
7
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.免疫特征作为预测标志物，用于预测黑色素瘤对检查点抑制剂免疫治疗的反应和总生存期。
Cancer Med. 2021 Mar;10(5):1562-1575. doi: 10.1002/cam4.3710. Epub 2021 Jan 15.
8
B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2.B4GALNT1 通过诱导神经节苷脂 GM2/GD2 诱导血管生成、锚定独立性生长和运动，并促进黑色素瘤的肿瘤发生。
Sci Rep. 2020 Jan 27;10(1):1199. doi: 10.1038/s41598-019-57130-2.
9
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.免疫佐剂、纳米颗粒和检查点抑制剂的癌症免疫疗法：免疫疗法治疗和跟踪反应的最新进展和挑战。
Pharmacol Ther. 2020 Mar;207:107456. doi: 10.1016/j.pharmthera.2019.107456. Epub 2019 Dec 19.
10
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.挽救性帕博利珠单抗联合激酶抑制剂治疗用于治疗间变性甲状腺癌。
J Immunother Cancer. 2018 Jul 11;6(1):68. doi: 10.1186/s40425-018-0378-y.
本文引用的文献
1
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.对连续进行CTLA-4和PD-1阻断治疗的肿瘤活检组织进行综合分子分析，揭示了反应和耐药的标志物。
Sci Transl Med. 2017 Mar 1;9(379). doi: 10.1126/scitranslmed.aah3560.
2
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.新型算法方法利用特定基因突变集预测肿瘤突变负荷并与免疫治疗临床结果相关联。
BMC Med. 2016 Oct 25;14(1):168. doi: 10.1186/s12916-016-0705-4.
3
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.靶向新一代测序鉴定出对PD-1阻断治疗反应的标志物。
Cancer Immunol Res. 2016 Nov;4(11):959-967. doi: 10.1158/2326-6066.CIR-16-0143. Epub 2016 Sep 26.
4
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.对抗CTLA4免疫疗法有反应的患者中存在复发性丝氨酸蛋白酶抑制剂B3和丝氨酸蛋白酶抑制剂B4突变。
Nat Genet. 2016 Nov;48(11):1327-1329. doi: 10.1038/ng.3677. Epub 2016 Sep 26.
5
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.肿瘤细胞中IFN-γ信号通路基因缺失作为抗CTLA-4治疗耐药机制
Cell. 2016 Oct 6;167(2):397-404.e9. doi: 10.1016/j.cell.2016.08.069. Epub 2016 Sep 22.
6
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.一项评估威罗菲尼（vemurafenib）继以伊匹单抗（ipilimumab）治疗未经治 BRAF 突变转移性黑色素瘤患者的 II 期研究。
J Immunother Cancer. 2016 Aug 16;4:44. doi: 10.1186/s40425-016-0148-7. eCollection 2016.
7
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.与黑色素瘤中PD-1阻断获得性耐药相关的突变
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
8
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.对纵向肿瘤样本中的免疫特征进行分析，有助于深入了解免疫检查点阻断反应的生物标志物和耐药机制。
Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.
9
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.替利莫吉尼联合伊匹单抗用于既往未治疗的不可切除ⅢB-Ⅳ期黑色素瘤
J Clin Oncol. 2016 Aug 1;34(22):2619-26. doi: 10.1200/JCO.2016.67.1529. Epub 2016 Jun 13.
10
Monitoring immune responses in the tumor microenvironment.监测肿瘤微环境中的免疫反应。
Curr Opin Immunol. 2016 Aug;41:23-31. doi: 10.1016/j.coi.2016.05.006. Epub 2016 May 27.
Zotero 插件